Sebastián Udry

TL;DR: In this paper, the effect of additional treatments combined with conventional therapy on pregnancy outcomes was examined in high-risk primary antiphospholipid syndrome (PAPS) patients to identify the most effective treatment strategy.

TL;DR: An international project about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS, and the group recently obtained the orphan designation of HCQ in antiphospholipid syndrome.

TL;DR: Major differences between groups were not observed in treatment rates, livebirths and thrombotic complications, and Fetal-maternal outcomes were similar in both groups when treated.

TL;DR: The findings reinforce the idea that triple positivity is a categorical risk factor for poor response to conventional treatment in women with obstetric antiphospholipid syndrome treated with conventional treatment.

TL;DR: It is necessary to perform studies on the medium and long-term outcome of children born by mothers with autoimmune diseases, treated with AZA, in order to show the safety of AZA exposure.